European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline...

LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.

RAHWAY, N.J.--(BUSINESS WIRE) September 4, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a...

Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood...

MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.

MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.

MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

RAHWAY, N.J.--(BUSINESS WIRE) August 27, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the...